Addex Therapeutics Company Leadership
| ADXN Stock | USD 7.71 0.05 0.65% |
Addex Therapeutics employs about 2 people. The company is managed by 7 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 0.29 employees per reported executive. Analysis of Addex Therapeutics' management performance can provide insight into the firm performance.
Addex Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Addex Therapeutics' future performance. Based on our forecasts, it is anticipated that Addex will maintain a workforce of about 18 employees by March 2026.Addex Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.159) % which means that it has lost $0.159 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7284) %, meaning that it created substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Addex Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 3rd of February 2026, Return On Assets is likely to grow to 0.80, while Return On Capital Employed is likely to drop (0.34). At this time, Addex Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 3rd of February 2026, Intangible Assets is likely to grow to about 30.8 M, while Total Assets are likely to drop about 9.1 M.As of the 3rd of February 2026, Common Stock Shares Outstanding is likely to grow to about 987.3 K, though Net Loss is likely to grow to (17.8 M). Almost 99.97 percent of Addex Therapeutics outstanding shares are held by general public with 0.03 % by other corporate entities.
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 767.2 K | Current Value 939 K | Avarage Shares Outstanding 3.3 M | Quarterly Volatility 17.9 M |
Addex Therapeutics Workforce Comparison
Addex Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 82.0. Addex Therapeutics holds roughly 2.0 in number of employees claiming about 2.44% of equities under Health Care industry.
Addex Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Addex Therapeutics Price Series Summation is a cross summation of Addex Therapeutics price series and its benchmark/peer.
Addex Therapeutics Notable Stakeholders
An Addex Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Addex Therapeutics often face trade-offs trying to please all of them. Addex Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Addex Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Timothy Dyer | CEO CoFounder | Profile | |
| Werner Henrichi | Consultant | Profile | |
| Mikhail Kalinichev | Head Science | Profile | |
| JeanPhilippe Rocher | Head Chemistry | Profile | |
| Roger MD | Chief Director | Profile | |
| Lnaic Teyssdou | Head Finance | Profile | |
| Robert Lutjens | Head Biology | Profile |
About Addex Therapeutics Management Performance
The success or failure of an entity such as Addex Therapeutics often depends on how effective the management is. Addex Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Addex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Addex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.76 | 0.80 | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | 0.76 | 0.80 | |
| Return On Equity | 0.84 | 0.88 |
Addex Therapeutics Workforce Analysis
Traditionally, organizations such as Addex Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Addex Therapeutics within its industry.Addex Therapeutics Manpower Efficiency
Return on Addex Therapeutics Manpower
| Revenue Per Employee | 202.1K | |
| Revenue Per Executive | 57.7K | |
| Net Income Per Employee | 3.5M | |
| Net Income Per Executive | 1M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 391.3K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in median. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Will Biotechnology sector continue expanding? Could Addex diversify its offerings? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Addex Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (9.24) | Revenue Per Share | Quarterly Revenue Growth (0.15) | Return On Assets | Return On Equity |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Addex Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Addex Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Addex Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.